Accenture (NYSE:ACN) said today that it inked a five-year deal with Roche (OTC:RHHBY) to incorporate its analytics platform into Roche’s digital diabetes management system.
According to the deal, Roche’s new digital “diabetes ecosystem” will be built on the Accenture Intelligent Patient Platform. The system reportedly allows Roche to collect and analyze data from diabetes patients in the U.S., Europe and Asia in an effort to develop more personalized care models.
“This collaboration agreement with Accenture is an exciting step forward to offering truly integrated diabetes management solutions,” Marcel Gmünder, Global Head of Roche Diabetes Care, said in prepared remarks. “The open diabetes platform we are creating will enable us to analyze large amounts of data through algorithms and put them into context, respond faster to the needs of people with diabetes, caregivers and healthcare systems and personalize treatment which all-in-all can lead to improved outcomes. The collaboration builds on the trusted relationship we have had over the years. It will enable us to drive digital health in diabetes forward and offer integrated diabetes management solutions and services to shape the way care is being provided in the future, for improved therapy outcomes and more sustainable healthcare systems.”
“Uncontrolled diabetes can lead to serious health problems but also bring about substantial economic loss to those affected by the disease, through direct medical costs and loss of work and wages,” Andrea Brückner, head of Accenture’s life science biz in Europe, Africa, the Middle East and Latin America, added. “We are collaborating with Roche to help combat this illness and increase the management of secondary health problems by working to change the standard of care and re-shaping the industry by seamlessly connecting patients, caregivers and healthcare providers to share information, data and insights to make better care decisions to deliver more precise, personalized support.”